The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I study of inotuzumab ozogamicin (INO) combined with R-GDP for relapsed CD22+ B-cell non-Hodgkin lymphoma (B-NHL).
Randeep S. Sangha
No relevant relationships to disclose
Andrew John Davies
Research Funding - Pfizer
Nam H. Dang
Honoraria - Pfizer
Research Funding - Pfizer
Michinori Ogura
Research Funding - Pfizer
M. Luisa Paccagnella
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Revathi Ananthakrishnan
Employment or Leadership Position - Pfizer
Erik Vandendries
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Goh Yeow Tee
No relevant relationships to disclose